Today, Celmatix, a next-generation women’s health company, has announced a commercial agreement with Oncotest-Teva Ltd, a subsidiary of Teva Pharmaceutical Industries Ltd. in Israel to bring the Fertilome test, the world’s first multigene panel test for a woman’s reproductive health and fertility, to the Israeli market.

Source link